

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2015

ATOSSA GENETICS INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

001-35610
(Commission file number)

26-4753208
(IRS Employer Identification No.)

2345 Eastlake Ave. East, Suite 201, Seattle, Washington 98102
(Address of principal executive offices and zip code)

(800) 351-3902
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure

On January 13, 2015, Atossa Genetics Inc. (“Atossa” or the “Company”) updated its corporate slide deck, which contains an overview of the Company and certain financial projections (the “Presentation”). A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

* * *

The Company is furnishing the information in this Current Report on Form 8-K to comply with Regulation FD. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in the Presentation may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. For example, the Company’s revenue forecast is a forward-looking statement. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with planned and ongoing product launches, expected levels of future revenues, expenditures, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its most recent annual report on form 10-K and subsequent quarterly reports on form 10-Q, each as amended and supplemented from time to time.

Item 9.01 Financial Statements and Exhibits.

99.1 Corporate presentation dated January 13, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ATOSSA GENETICS INC.

Date: January 14, 2015

By: /s/ Kyle Guse

Kyle Guse
Chief Financial Officer, General Counsel and Secretary



Atossa
GENETICS



The Breast Care Company™

NASDAQ: ATOS

WWW.ATOSSAGENETICS.COM

JANUARY 13, 2015



Forward-Looking Statements



Some of the information presented herein may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. For example, our revenue forecast is a forward-looking statement. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with planned and ongoing product launches, expected levels of future revenues, expenditures, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its most recent annual report on form 10-K and subsequent quarterly reports on form 10-Q, each as amended and supplemented from time to time.

Corporate Summary



Atossa Genetics Inc. (IPO November 8, 2012)	NASDAQ: ATOS
Our Mission	Prevent Breast Cancer
Stock Price (Jan. 7, 2015; 52-Week Range)	\$1.27 (\$.80 to \$3.28)
Shares Outstanding (Nov. 12, 2014)	24.6M
Inside Ownership	5.7M (23%)
Daily Volume (50-day avg. at Jan. 7, 2015)	347,594
Market Capitalization (Jan. 7, 2015)	\$32M
Forecast 2015 Total Revenue	\$8M
Debt (Sept. 30, 2014)	\$0
Cash (Sept. 30, 2014)	\$11.4M
Full-time Employees	21
2014 Avg. Monthly Cash Used in Operations (Sept. 30)	\$870,683
Corporate Headquarters	Seattle, Washington
Web Address	www.atossagenetics.com



Current Breast Health Tools Inadequate




Algorithms

70% have NO risk factors!

Breast Exam

NOT Recommended!



U.S. Preventive Services
TASK FORCE

Biopsy

Only 1%

105 MM U.S. Women

Imaging

Mammography
ONLY FOR women 50-74



1. Patented collection devices

2. Proprietary PBD diagnostic services

3. Patented pharmaceuticals for PBD



Note: Certain devices, tests and treatments are not cleared or approved, separately or as a system, for sale in the U.S.

Patented Collection Devices



Non U.S. Market – ForeCYTE*

- ✧ Intended for the collection of NAF for cytological testing.
- ✧ Reusable, hand-held pump.
- ✧ CE Marked for Q1 European launch



U.S. Market – FullCYTE

- ✧ Intended for the collection of ductal fluid for cytological testing.
- ✧ Single use only.
- ✧ Third party literature
- ✧ Q1 US launch



FullCYTE Microcatheters*



- Intended for ductal lavage – collects NAF from each duct.
- Also intended for targeted drug delivery.
- 2015 launch expected.



Breast specimen cytology

Pharmacogenomics





A Product/Territory/Partner Specific Program



Additional Partners Will Be Sought



Fisher HealthCare, McKesson, and Millennium currently under contract for ForeCYTE only.



A Service/Partner Specific Program



Pharmacogenomics



Cytology



Additional Services/Partners Will Be Sought



PBD Treatment Options-Now and Future



Current Treatment Option Is Oral Hormonal Therapy



- Highly effective with >80% reduction in breast cancer in women with PBD

BUT

- Serious and life-threatening systemic side effects

MEANS

- Only 5% of women get therapy


Future Treatments by Atossa Genetics Will Be Local



- Based on anti-estrogen treatments previously approved by FDA


WITH

- Localized treatment intended to reduce side effects



Potential 10 MM Patient Population - in US

All Women in the U.S.: 18-73 (105M)



Income Statement YTD



(\$ 000's)	Sept. 30, 2014
Revenue – Services	\$37
Revenue – Products	0
Total Gross Revenue	37
Cost of Revenue	(0)
Gross Profit	37
Total Operating Exp.	(8,880)
Operating Loss	(8,843)
Net Loss	\$(8,845)

Balance Sheet – September 30, 2014



Assets (\$000's)		Liabilities (\$000's)	
Current Assets:		Current Liabilities:	
Cash	\$11,374	Accounts Pay.	\$439
Accts Rec.	29	Accrued Exp.	393
Prepd, Other	313	Other	708
Total	11,716	Total	1,540
Other Assets	691	Equity	15,233
Intangible	4,365		
Total Assets	\$16,772	Total Liab. & Equity	\$16,772

Capitalization



Sept. 30, 2014 (shares 000's)	
Common Stock	24,564
Preferred Stock	0
Warrants (\$1.92)	6,033
Options Granted	3,464
Total Outstanding	34,061

Financial Highlights



- ✓ Forecasted 2015 Total Revenue of \$8.0 M
- ✓ 34.1 M shares outstanding provides leverage
- ✓ No debt, no preferred stock
- ✓ Scalable contract manufacturing and low-capital laboratory services





- Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer
- Kyle Guse, CPA, Esq., MBA, CFO and General Counsel
- Jelle Kylstra, M.D., MBA, VP Clinical R&D
- Christopher Destro, Sr. VP Sales and Marketing
- Scott Youmans, Sr. VP Operations
- John Sawyer, Sr. VP Global Regulatory and QA
- Pieter van der Poel, VP European Commercial Operations



- ✓ 2015 Forecasted Total Revenue of \$8.0 M from Two-Pronged Product-Service Financial Model
- ✓ 2015 Pharmaceutical Clinical Trials Drive Additional Value
- ✓ Multi-Billion Dollar Diagnostic and Therapeutic Markets - Women's Health Driven
- ✓ 148 Issued Patents Secure Shareholder Value
- ✓ Experienced Management Team Supports Execution





Atossa
G E N E T I C S

The Breast Care Company™

NASDAQ: ATOS
WWW.ATOSSAGENETICS.COM

